Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000350

Drug Information
SynonymsDB08764; UNII-YO460OQ37K; 338992-00-0; CHEMBL24828; AC1MIWRU; Zactima, ZD6474; ||Zactima; CH 331; ZD 6474|; Vandetanib; Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; C452423; Kinome_3316; LS-184394; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-; EN002713; NCGC00167513-01; CID3081361; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; NSC744325; ZD 6474; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; Zactima; EC-000.2359; AZD-6474; 443913-73-3; Vandetanib, Zactima, ZD6474; MolPort-005-942-399; S1046_Selleck; ZD-6474; F9995-0087; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib [INN]; AC-5251; CH-331; CHEBI:49960; 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; I14-1942; Vandetanib (JAN/INN); D06407; 2ivu; ZD6474
IndicationBreast, thyroid tumours, multiple myeloma, brain, head & neck cancer
[ICD9: 140-149, 140-199, 140-229, 203.0, 210-229   ICD10: C00-C75, C00-C96, C07-C14, C32, C33, C7A, C7B, C90.0, D10-D36, D3A]
Phase II    
Solid tumours, NSCLC
[ICD9: 140-199, 162, 210-229   ICD10: C00-C75, C33, C34, C7A, C7B, D10-D36, D3A]
Phase III    

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 443913-73-3
PubChem Compound IDCID 3081361.
PubChem Substance IDSID 3882431.
SuperDrug ATC IDL01XE12
TargetEpidermal growth factor receptorInhibitor[1][2]
Epidermal growth factor receptorMultitarget[1][2]
Proto-oncogene tyrosine-protein kinase receptor retInhibitor[1][2]
Proto-oncogene tyrosine-protein kinase receptor retMultitarget[1][2]
Vascular endothelial growth factor receptor 2Inhibitor[1][2]
Vascular endothelial growth factor receptor 2Multitarget[1][2]
Ref 1A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 2AstraZeneca. Product Development Pipeline. January 29 2009. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543